695 related articles for article (PubMed ID: 19027852)
21. Influence of humidity on the phase behavior of API/polymer formulations.
Prudic A; Ji Y; Luebbert C; Sadowski G
Eur J Pharm Biopharm; 2015 Aug; 94():352-62. PubMed ID: 26117187
[TBL] [Abstract][Full Text] [Related]
22. Influence of lidocaine forms (salt vs. freebase) on properties of drug-eudragit® L100-55 extrudates prepared by reactive melt extrusion.
Liu X; Ma X; Kun E; Guo X; Yu Z; Zhang F
Int J Pharm; 2018 Aug; 547(1-2):291-302. PubMed ID: 29883791
[TBL] [Abstract][Full Text] [Related]
23. Modulation of drug release by utilizing pH-independent matrix system comprising water soluble drug verapamil hydrochloride.
Baviskar D; Sharma R; Jain D
Pak J Pharm Sci; 2013 Jan; 26(1):137-44. PubMed ID: 23261739
[TBL] [Abstract][Full Text] [Related]
24. Spray Encapsulation as a Formulation Strategy for Drug-Based Room Temperature Ionic Liquids: Exploiting Drug-Polymer Immiscibility to Enable Processing for Solid Dosage Forms.
Stocker MW; Healy AM; Ferguson S
Mol Pharm; 2020 Sep; 17(9):3412-3424. PubMed ID: 32852215
[TBL] [Abstract][Full Text] [Related]
25. Modulation of drug release kinetics from hydroxypropyl methyl cellulose matrix tablets using polyvinyl pyrrolidone.
Hardy IJ; Windberg-Baarup A; Neri C; Byway PV; Booth SW; Fitzpatrick S
Int J Pharm; 2007 Jun; 337(1-2):246-53. PubMed ID: 17306477
[TBL] [Abstract][Full Text] [Related]
26. Formulation and characterizations of delayed release multi particulates system of indomethacin: optimization by response surface methodology.
Nandy BC; Mazumder B
Curr Drug Deliv; 2014; 11(1):72-86. PubMed ID: 24783236
[TBL] [Abstract][Full Text] [Related]
27. Hot melt extrusion for amorphous solid dispersions: temperature and moisture activated drug-polymer interactions for enhanced stability.
Sarode AL; Sandhu H; Shah N; Malick W; Zia H
Mol Pharm; 2013 Oct; 10(10):3665-75. PubMed ID: 23961978
[TBL] [Abstract][Full Text] [Related]
28. Drug release from hydroethanolic gels. Effect of drug's lipophilicity (logP), polymer-drug interactions and solvent lipophilicity.
Sawant PD; Luu D; Ye R; Buchta R
Int J Pharm; 2010 Aug; 396(1-2):45-52. PubMed ID: 20540996
[TBL] [Abstract][Full Text] [Related]
29. Physical stability of API/polymer-blend amorphous solid dispersions.
Lehmkemper K; Kyeremateng SO; Bartels M; Degenhardt M; Sadowski G
Eur J Pharm Biopharm; 2018 Mar; 124():147-157. PubMed ID: 29269154
[TBL] [Abstract][Full Text] [Related]
30. A Systematic Study of Molecular Interactions of Anionic Drugs with a Dimethylaminoethyl Methacrylate Copolymer Regarding Solubility Enhancement.
Saal W; Ross A; Wyttenbach N; Alsenz J; Kuentz M
Mol Pharm; 2017 Apr; 14(4):1243-1250. PubMed ID: 28287743
[TBL] [Abstract][Full Text] [Related]
31. Ability of different polymers to inhibit the crystallization of amorphous felodipine in the presence of moisture.
Konno H; Taylor LS
Pharm Res; 2008 Apr; 25(4):969-78. PubMed ID: 17520180
[TBL] [Abstract][Full Text] [Related]
32. Interaction between Eudragit® E100 and anionic drugs: addition of anionic polyelectrolytes and their influence on drug release performance.
Quinteros DA; Manzo RH; Allemandi DA
J Pharm Sci; 2011 Nov; 100(11):4664-73. PubMed ID: 21647887
[TBL] [Abstract][Full Text] [Related]
33. Effects of polyvinylpyrrolidone both as a binder and pore-former on the release of sparingly water-soluble topiramate from ethylcellulose coated pellets.
Yang M; Xie S; Li Q; Wang Y; Chang X; Shan L; Sun L; Huang X; Gao C
Int J Pharm; 2014 Apr; 465(1-2):187-96. PubMed ID: 24530810
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of crystal nucleation and growth by water-soluble polymers and its impact on the supersaturation profiles of amorphous drugs.
Ozaki S; Kushida I; Yamashita T; Hasebe T; Shirai O; Kano K
J Pharm Sci; 2013 Jul; 102(7):2273-81. PubMed ID: 23658029
[TBL] [Abstract][Full Text] [Related]
35. Stabilization of low glass transition temperature indomethacin formulations: impact of polymer-type and its concentration.
Chokshi RJ; Shah NH; Sandhu HK; Malick AW; Zia H
J Pharm Sci; 2008 Jun; 97(6):2286-98. PubMed ID: 17879977
[TBL] [Abstract][Full Text] [Related]
36. Characterization and stability of solid dispersions based on PEG/polymer blends.
Bley H; Fussnegger B; Bodmeier R
Int J Pharm; 2010 May; 390(2):165-73. PubMed ID: 20132875
[TBL] [Abstract][Full Text] [Related]
37. Insights into the mechanisms of chitosan-anionic polymers-based matrix tablets for extended drug release.
Li L; Wang L; Li J; Jiang S; Wang Y; Zhang X; Ding J; Yu T; Mao S
Int J Pharm; 2014 Dec; 476(1-2):253-65. PubMed ID: 25290814
[TBL] [Abstract][Full Text] [Related]
38. Long-Term Physical Stability of PVP- and PVPVA-Amorphous Solid Dispersions.
Lehmkemper K; Kyeremateng SO; Heinzerling O; Degenhardt M; Sadowski G
Mol Pharm; 2017 Jan; 14(1):157-171. PubMed ID: 28043133
[TBL] [Abstract][Full Text] [Related]
39. Enteric polymers as acidifiers for the pH-independent sustained delivery of a weakly basic drug salt from coated pellets.
Körber M; Ciper M; Hoffart V; Pearnchob N; Walther M; Macrae RJ; Bodmeier R
Eur J Pharm Biopharm; 2011 Aug; 78(3):447-54. PubMed ID: 21443950
[TBL] [Abstract][Full Text] [Related]
40. The Influence of the Strength of Drug-Polymer Interactions on the Dissolution of Amorphous Solid Dispersions.
Amponsah-Efah KK; Mistry P; Eisenhart R; Suryanarayanan R
Mol Pharm; 2021 Jan; 18(1):174-186. PubMed ID: 33332132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
